A Phase II Study of Perioperative Capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601).

Tetsuji TerazawaJin MatsuyamaMasahiro GotoRyohei KawabataShunji EndoMotohiro ImanoShoichiro FujitaYusuke AkamaruHirokazu TaniguchiMitsutoshi TatsumiSang-Woong LeeYoshitaka KurisuHisato KawakamiYukinori KurokawaToshio ShimokawaDaisuke SakaiTakeshi KatoKazumasa FujitaniTaroh Satoh

Published in: The oncologist (2019)

Perioperative CapeOx showed good feasibility and favorable efficacy with sufficient pathological response, although statistical significance at .058 did not reach the commonly accepted cutoff of .05. The data obtained using this novel approach warrant further investigations.

Keyphrases

phase ii study
locally advanced
open label
cardiac surgery
patients undergoing
electronic health record
placebo controlled
rectal cancer
acute kidney injury
squamous cell carcinoma
clinical trial
radiation therapy
data analysis
study protocol
machine learning